A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model

Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4

(2010) M. Arakawa et al.   DIABETES

RETRACTED ARTICLE: A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells

(2010) Y. Hattori et al.   DIABETOLOGIA

Incretin-Based Therapies for Type 2 Diabetes Mellitus: Current Status and Future Prospects

(2010) Scott R Drab   PHARMACOTHERAPY

Endothelial Dysfunction

(2009) Paul M. Vanhoutte   CIRCULATION JOURNAL

A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules

(2009) Hongbin Liu et al.   JOURNAL OF ENDOCRINOLOGY

Exendin-4 inhibits interleukin-1β-induced iNOS expression at the protein level, but not at the transcriptional and posttranscriptional levels, in RINm5F β-cells

(2009) Jung-Hoon Kang et al.   JOURNAL OF ENDOCRINOLOGY

Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes

(2008) J.-P. Courrèges et al.   DIABETIC MEDICINE

Exendin-(9–39) Corrects Fasting Hypoglycemia inSUR-1–/–Mice by Lowering cAMP in Pancreatic β-Cells and Inhibiting Insulin Secretion

(2008) Diva D. De León et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The Role of Incretins in Glucose Homeostasis and Diabetes Treatment

(2008) W. Kim et al.   PHARMACOLOGICAL REVIEWS

High glucose induces plasminogen activator inhibitor-1 expression through Rho/Rho-kinase-mediated NF-κB activation in bovine aortic endothelial cells

(2007) Hitoshi Iwasaki et al.   ATHEROSCLEROSIS